Hennion & Walsh Asset Management Inc. Purchases 48,710 Shares of MorphoSys AG (NASDAQ:MOR)

Hennion & Walsh Asset Management Inc. increased its position in shares of MorphoSys AG (NASDAQ:MOR) by 71.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 116,901 shares of the company’s stock after acquiring an additional 48,710 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in MorphoSys were worth $2,121,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of MOR. TD Asset Management Inc increased its holdings in shares of MorphoSys by 153.8% in the 4th quarter. TD Asset Management Inc now owns 361,138 shares of the company’s stock worth $3,575,000 after buying an additional 218,870 shares during the last quarter. Henry James International Management Inc. bought a new position in shares of MorphoSys in the 4th quarter worth $426,000. Quadrant Capital Group LLC increased its holdings in shares of MorphoSys by 204.8% in the 4th quarter. Quadrant Capital Group LLC now owns 5,572 shares of the company’s stock worth $55,000 after buying an additional 3,744 shares during the last quarter. Kynam Capital Management LP bought a new position in shares of MorphoSys in the 4th quarter worth $41,923,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of MorphoSys by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 17,437 shares of the company’s stock worth $173,000 after buying an additional 4,421 shares during the last quarter. Institutional investors own 18.38% of the company’s stock.

MorphoSys Stock Up 0.2 %

MOR traded up $0.03 during trading on Friday, hitting $18.20. 24,526 shares of the stock traded hands, compared to its average volume of 73,660. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 4.98. The firm has a 50-day moving average of $18.21 and a 200 day moving average of $15.77. MorphoSys AG has a 12-month low of $4.18 and a 12-month high of $19.50.

MorphoSys (NASDAQ:MOR) last announced its quarterly earnings results on Monday, April 29th. The company reported ($2.24) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($1.73). The firm had revenue of $29.86 million for the quarter, compared to analysts’ expectations of $48.99 million. MorphoSys had a negative net margin of 226.79% and a negative return on equity of 694.31%. Research analysts anticipate that MorphoSys AG will post -2.43 earnings per share for the current year.

Analyst Ratings Changes

Separately, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $18.25 target price (up previously from $17.00) on shares of MorphoSys in a report on Thursday, March 14th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, MorphoSys has an average rating of “Hold” and an average target price of $11.78.

MorphoSys Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.